L-NAME HCl

Catalog No.S2877 Synonyms: NG-Nitroarginine methyl ester, N-Nitro-L-arginine methylester

For research use only.

L-NAME HCl (NG-Nitroarginine methyl ester, N-Nitro-L-arginine methylester) is a nonselective inhibitor of nitric oxide synthetases (NOS) for nNOS (bovine), eNOS (human), and iNOS (murine), with Ki of 15 nM, 39 nM and 4.4 μM, respectively.

L-NAME HCl Chemical Structure

CAS No. 51298-62-5

Selleck's L-NAME HCl has been cited by 27 publications

Purity & Quality Control

Choose Selective NOS Inhibitors

Biological Activity

Description L-NAME HCl (NG-Nitroarginine methyl ester, N-Nitro-L-arginine methylester) is a nonselective inhibitor of nitric oxide synthetases (NOS) for nNOS (bovine), eNOS (human), and iNOS (murine), with Ki of 15 nM, 39 nM and 4.4 μM, respectively.
Targets
nNOS [1]
(Cell-free assay)
eNOS [1]
(Cell-free assay)
15 nM(Ki) 39 nM(Ki)
In vitro

NG-nitro-L-arginine methyl ester (L-NAME; at 0.1-100 mM) causes concentration-dependent inhibition of the Ca2(+)-dependent endothelial NO synthase from porcine aortae. L-NAME causes an endothelium-dependent contraction and an inhibition of the endothelium-dependent relaxation induced by acetylcholine (ACh) in aortic rings. [2] In another research, Viability of rMC-1 cells or BREC in 25 mM glucose is significantly less than at 5 mM glucose, and this cell death is inhibited by l-NAME in both cell types. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
mouse BV2 cells MUXGeY5kfGmxbjDhd5NigQ>? MlXiNlQhcA>? NGfkdWVKdmirYnn0bY9vKG:oIF7peJJq[yCxeHnk[UB{gW62aHHz[UBi[3Srdnn0fUBqdiCvb4Xz[UBDXjJiY3XscJMh[XO|ZYPz[YQh[XNiTGDTMYlv\HWlZXSgUm8heHKxZIXjeIlwdiCjZoTldkAzPCCqcoOgZpkhT3KrZYPzJJJm[WO2aX;uMEBKSzVyPUG4Mlkh|ryP MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTN5N{O2PEc,OjF|N{ezOlg9N2F-
mouse RAW264.7 cells M4nRc2Z2dmO2aX;uJIF{e2G7 NVzHOIhEOTdvMkCgbC=> NXXaOJdKSW62aXnu[oxidW2jdH;yfUBi[3Srdnn0fUBqdiCvb4Xz[UBTSVd{NkSuO{Bk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIFnGUk1o[W2vYT;MVHMue3SrbYXsZZRm\CCwaYTybYMhd3irZHWgdJJw\HWldHnvckBi\nSncjCxO{B1dyB{MDDodpMh[nliR4Lp[ZN{KGG|c3H5MEBKSzVyPUK3MlE{KM7:TR?= MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTN3OUC2PEc,OTl|NUmwOlg9N2F-
HUVEC M3PBN2Z2dmO2aX;uJIF{e2G7 NWftbGJGSWKrbHn0fUB1dyCrbnjpZol1KGOxbo\ldpNqd25ib3[gX|NJZUxvQYLnJJRwKFt|SG3MMYNqfHK3bHzpcoUh[2G2YXz5foVlKGK7IHXu[I91cGWuaXHsJG5QWyBqZTDOU3MqKG[{b32gTHVXTUNiY3XscJMtKEmFNUC9Nk44|ryP Mkn2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTF|Mke1PFAoRjFzM{K3OVgxRC:jPh?=
DLD-1 MYTGeY5kfGmxbjDhd5NigQ>? NEPZcFVC[mmuaYT5JJRwKGmwaHnibZQh[2:wdnXyd4lwdiCxZjDbN2heVC2DcnegeI8hYzOKXVytZ4l1enWubHnu[UBk[XSjbIn6[YQh[nliaX7keYNq[mynIF7PV{ApcSCQT2OpJIZzd21iaIXtZY4hTEyGLUGgZ4VtdHNuIFnDOVA:OTUQvF2= M2iweVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFzM{K3OVgxLz5zMUOyO|U5ODxxYU6=
BV2 NHfveGtHfW6ldHnvckBie3OjeR?= NVnsNnVyUW6qaXLpeIlwdiCxZjDOU3Mu\GWyZX7k[Y51KG6rdILpZ{BwgGmmZTDwdo9lfWO2aX;uJIlvKG2xdYPlJGJXOiClZXzsd{whUUN3ME2zOu69VQ>? M4O4SFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5MES2NlU2Lz5zN{C0OlI2PTxxYU6=
BV2 MkPiSpVv[3Srb36gZZN{[Xl? M1u5cWlvcGmkaYTpc44hd2Zibnn0dolkKG:6aXTlJJN6dnSqYYPlJIlvKG2xdYPlJGJXOiClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJGxRWy2rbnT1Z4VlKE6RIIDyc4R2[3Srb36sJGlEPTB;MkCuNe69VQ>? NXvVb2J1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUixOlE6PDJpPkG4NVYyQTR{PD;hQi=>
BV2 NF\wXHBHfW6ldHnvckBie3OjeR?= NGDiWHNKdmirYnn0bY9vKG:oIHnOU3MudWWmaXH0[YQhVk9icILv[JVkfGmxbjDpckBNWFNvaX7keYNm\CCvb4Xz[UBDXjJiY3XscJMtKEmFNUC9NlUvQM7:TR?= NVTscoltRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi5NlY4OTBpPkG4PVI3PzFyPD;hQi=>
BV2 M2LYcGFvfGmrbn\sZY1u[XSxcomgZZN{[Xl? Mo\5NlQhcHK| MmixRY51cWmwZnzhcY1ifG:{eTDhZ5Rqfmm2eTDpckBud3W|ZTDCWlIh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDMVHMucW6mdXPl[EBqVk:VLXTldIVv\GWwdDDubZRzcXSnIIDyc4R2[3Srb36gZYZ1\XJiMkSgbJJ{KGK7IFfybYV{eyCvZYToc4QtKEmFNUC9NlUvQM7:TR?= NH3KT4U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUCyPFg6QCd-MkGwNlg5QTh:L3G+
BV2 Mn3aSpVv[3Srb36gZZN{[Xl? MmXPTY5pcWKrdHnvckBw\iCrTl;TJIlvKG2xdYPlJGJXOiCvaXPyc4dtcWGuIHPlcIx{KGG|c3Xzd4VlKGG|IF7PJJBzd2S3Y4Tpc44tKEmFNUC9NlUvQM7:TR?= NIe4Nng9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUGxOVI2OSd-MkGxNVUzPTF:L3G+
RAW264.7 Mn7TSpVv[3Srb36gZZN{[Xl? MYCxJIhz M{P5XmlvcGmkaYTpc44hd2ZiTGDTMYlv\HWlZXSgcol1emmlIH;4bYRmKHC{b3T1Z5Rqd25iaX6gcY92e2ViUlHXNlY1NjdiY3XscJMheHKnaX7jeYJifGWmIIfpeIgh[2:vcH;1coQh\m:{IEGgbJIh[mWob4LlJIV5eG:|dYLlJJRwKEySUzDt[YF{fXKnZDDh[pRmeiB{NDDodpMh[nliR4Lp[ZN{KHKnYXP0bY9vKG2ndHjv[EwhUUN3ME20PE42|ryP Mo\iQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF2M{W4O|QoRjJzNEO1PFc1RC:jPh?=
Sf9 M3S0RmZ2dmO2aX;uJIF{e2G7 M125bVQ2KG2rboO= MY\Jcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KGWQT2Og[ZhxemW|c3XkJIlvKFOoOTDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKGOxbo\ldpNqd25ib3[gX|NJZS2OLXHy[4lvcW6nIITvJHs{UF1vTD3jbZRzfWyuaX7lJIFnfGW{IES1JI1qdnNiYomgcIlyfWmmIIPjbY51cWyuYYTpc44h[2:3boTpcoctKEmFNUC9NE43QM7:TR?= MkK1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7MkOxNVYoRjJzOUKzNVE3RC:jPh?=
Sf9 M4nZfWZ2dmO2aX;uJIF{e2G7 M{Tu[FQ2KG2rboO= NFjNOnVKdmirYnn0bY9vKG:oIHj1cYFvKHKnY3;tZolv[W62IH7OU3Mh\XiycnXzd4VlKGmwIGPmPUBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHPvcpZmenOrb36gc4YhYzOKXT3MMYFz\2mwaX7lJJRwKFt|SG2tUE1kcXS{dXzsbY5mKGGodHXyJFQ2KG2rboOgZpkhdGmzdXnkJJNkcW62aXzsZZRqd25iY3;1cpRqdmduIFnDOVA:OC54Od88US=> NV;1blFmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5NlMyOTZpPkKxPVI{OTF4PD;hQi=>
Sf9 MX\GeY5kfGmxbjDhd5NigQ>? MVi0OUBucW6| MkfoTY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCrTl;TJIV5eHKnc4Pl[EBqdiCVZkmgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iClb372[ZJ{cW:wIH;mJHs{UF1vTD3hdodqdmmwZTD0c{BcO0ifLVytZ4l1enWubHnu[UBi\nSncjC0OUBucW6|IHL5JIxqeXWrZDDzZ4lvfGmubHH0bY9vKGOxdX70bY5oNCCLQ{WwQVAvQDQQvF2= MmP3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7MkOxNVYoRjJzOUKzNVE3RC:jPh?=
BV2 MX7GeY5kfGmxbjDhd5NigQ>? NIT2R3UzPCCqcoO= NH;wPZpKdmirYnn0bY9vKG:oIHnOU3MudWWmaXH0[YQhdmm2cnnjJI95cWSnIIDyc4R2[3Srb36gbY4hVFCVLYP0bY12dGG2ZXSgcY92e2ViQm[yJINmdGy|IH3lZZN2emWmIHHmeIVzKDJ2IHjyd{Bw\iCyb4P0MZN1cW23bHH0bY9vKGK7IFfybYV{eyC{ZXHjeIlwdiCvZYToc4QtKEmFNUC9NVMvOzYQvF2= NWHyd4RuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxNVU3OThpPkKyNVE2PjF6PD;hQi=>
BV2 NFewO5NHfW6ldHnvckBie3OjeR?= NGTEXpMyKGi{ NFizW|VKdmirYnn0bY9vKG:oIFzQV{1qdmS3Y3XkJG5QKHC{b3T1Z5Rqd25iaX6gcY92e2ViQm[yJINmdGy|IIDy[Ylv[3WkYYTl[EBnd3JiMTDodkBnd2yub4fl[EBjgSCOUGOgZYRlcXSrb36gcYVie3W{ZXSgZYZ1\XJiMkSgbJJ{KGK7IFfybYV{eyCjc4PhfUwhUUN3ME2yOE44|ryP M1OwdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5NUi4N|I3Lz5{N{W4PFMzPjxxYU6=
RAW264.7 NIHGN5pCdnSraX7mcIFudWG2b4L5JIF{e2G7 MoTkNkBpenN? NFzHUYZCdnSraX7mcIFudWG2b4L5JIFkfGm4aYT5JIlvKG2xdYPlJHJCXzJ4ND63JINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiTGDTMYlv\HWlZXSgcol1emmlIH;4bYRmKHC{b3T1Z5Rqd25icILlbY5kfWKjdHXkJIZweiB{IHjyd{Bnd2yub4fl[EBjgSCOUGOgd5RqdXWuYYTpc44hdWWjc4Xy[YQh[W[2ZYKgNVghcHK|IHL5JGdzcWW|czDhd5NigSxiSVO1NF0{OC54zszN M4Tr[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MEm5NFEyLz5{OEC5PVAyOTxxYU6=
SK-N-MC MmKwdWhVWyCjc4PhfS=> MnG0dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tUWMh[2WubIO= NY\YSZRtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-SH M3O2bZFJXFNiYYPzZZk> NH:0R2NyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1UUCClZXzsdy=> MnOzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
NB1643 M{flcZFJXFNiYYPzZZk> NXTtbVJQeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IF7CNVY1OyClZXzsdy=> NVvvXoRXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
RAW264.7 M{[wbGFvfGlvaX7mcIFudWG2b4L5JIF{e2G7 NWLJUFY3OTdidH:gNlAhcHJ? NIrNTmZCdnSrLXnu[oxidW2jdH;yfUBi[3Srdnn0fUBqdiCPdYOgcZV{[3WudYOgLI1wfXOnKTDSRXczPjRwNzDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKEmITj3nZY1u[S:OUGOtbY5lfWOnZDDOU{Bxem:mdXP0bY9vKGGodHXyJFE4KHSxIEKwJIhzKGK7IFfybYV{eyCjc4PhfUwhUUN3ME2yN{4zOc7:TR?= NUH5eJVQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPzh7MD:nQmNpTU2ETEyvZV4>
RAW264.7 MYfBcpRqNWmwZnzhcY1ifG:{eTDhd5NigQ>? M3TG[|E4KHSxIEKwJIhz NVXsdXZkSW62aT3pcoZt[W2vYYTvdpkh[WO2aY\peJkhcW5iTYXzJI12e2O3bIXzJEhud3W|ZTmgVmFYOjZ2LkegZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCLRl6t[4FudWFxTGDTMYlv\HWlZXSgcol1emmlIH;4bYRmKHC{b3T1Z5Rqd25iYX\0[ZIhOTdidH:gNlAhcHJiYomgS5Jq\XO|IHHzd4F6NCCLQ{WwQVI3NjJzzszN MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly3PFkxNyd-Q3jFUWJNRC:jPh?=
In vivo L-NAME (0.03-300 mg kg-1, i.v.) induces a dose-dependent increase in mean systemic arterial blood pressure accompanied by bradycardia. L-NAME (100 mg kg-1, i.v.) inhibits significantly the hypotensive responses to ACh and bradykinin. The increase in blood pressure and bradycardia produced by L-NAME is reversed by L-arginine (30-100 mg kg-1, i.v.) in a dose-dependent manner. [2]

Protocol (from reference)

Kinase Assay:[1]
  • Enzyme Assay:

    The oxidation of L-arginine is monitored by the conversion of [3H]- or [14C]-arginine to L-citrulline which separates L-citrulline from L-arginine by Dowex 50x8-200 (Na) chromatography. Typical reaction mixtures (100 pL) contains 50 mM HEPES, pH 7.0, 8 pM tetrahydrobiopterin, 1 mM CaC12, 0.01 mg/mL calmodulin, 0.5 mM EDTA, 0.450 pM [14C]-arginine (30000 cpm), and 100-200 pM NADPH. The cNOS-catalyzed oxidation of NADPH to NADP+ is monitored by the reduction of absorbance at 340 nm with a Kontron 860 spectrophotometer in a volume of 300 pL. All reactions are at 30 ℃ unless otherwise indicated.

Cell Research:[3]
  • Cell lines: rMC-1 cells
  • Concentrations: 1 mM
  • Incubation Time: 5 days
  • Method: rMC-1 cells are incubated in 5 or 25 mM glucose, with or without l-NAME (1 mM). Media is changed every other day for up to 5 days. BREC cells are incubated in 5 or 25 mM glucose as well as inhibitor as described above for 5 days. Cell death is determined by light microscopy using a hemocytometer and a 0.4% trypan blue dye exclusion method. The number of cells that do not exclude the dye is expressed per 1,000 total cells. A minimum of 800 cells is counted per assay (8 dishes, >100 cells counted per dish), and the assay is replicated three times on different days.
Animal Research:[2]
  • Animal Models: Male Wistar rats
  • Dosages: 100 mg/kg
  • Administration: i.v.

Solubility (25°C)

In vitro

Water 54 mg/mL
(200.22 mM)
DMSO Insoluble
Ethanol Insoluble

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
Saline
For best results, use promptly after mixing.

30 mg/mL

Chemical Information

Molecular Weight 269.69
Formula

C7H15N5O4.HCl

CAS No. 51298-62-5
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles COC(=O)C(CCCN=C(N)N[N+](=O)[O-])N.Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy L-NAME HCl | L-NAME HCl supplier | purchase L-NAME HCl | L-NAME HCl cost | L-NAME HCl manufacturer | order L-NAME HCl | L-NAME HCl distributor